Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 43 | 2020 | 852 | 8.660 |
Why?
|
| Brain Ischemia | 31 | 2019 | 299 | 7.160 |
Why?
|
| Neuroprotective Agents | 10 | 2016 | 53 | 2.530 |
Why?
|
| Tissue Plasminogen Activator | 7 | 2016 | 108 | 2.160 |
Why?
|
| Cerebrovascular Circulation | 12 | 2012 | 125 | 2.060 |
Why?
|
| Clinical Trials as Topic | 15 | 2016 | 380 | 2.030 |
Why?
|
| Infarction, Middle Cerebral Artery | 7 | 2009 | 57 | 2.020 |
Why?
|
| Periodicals as Topic | 4 | 2017 | 163 | 1.710 |
Why?
|
| Thrombectomy | 3 | 2019 | 103 | 1.650 |
Why?
|
| Endovascular Procedures | 4 | 2019 | 320 | 1.600 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 10 | 2009 | 92 | 1.440 |
Why?
|
| Thrombolytic Therapy | 7 | 2016 | 157 | 1.240 |
Why?
|
| Editorial Policies | 2 | 2017 | 49 | 1.220 |
Why?
|
| Reperfusion Injury | 4 | 2016 | 48 | 1.090 |
Why?
|
| Disease Models, Animal | 14 | 2013 | 1795 | 1.090 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2009 | 216 | 1.070 |
Why?
|
| Fibrinolytic Agents | 4 | 2010 | 149 | 1.050 |
Why?
|
| Ischemic Attack, Transient | 4 | 2018 | 76 | 0.970 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2009 | 1333 | 0.890 |
Why?
|
| Rats | 17 | 2013 | 1806 | 0.870 |
Why?
|
| Reperfusion | 5 | 2010 | 25 | 0.820 |
Why?
|
| Time Factors | 16 | 2019 | 3232 | 0.810 |
Why?
|
| Treatment Outcome | 13 | 2020 | 3823 | 0.790 |
Why?
|
| Drug Design | 3 | 2010 | 137 | 0.760 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 154 | 0.700 |
Why?
|
| Anticoagulants | 5 | 2020 | 389 | 0.700 |
Why?
|
| Animals | 31 | 2016 | 17868 | 0.690 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2006 | 121 | 0.630 |
Why?
|
| Humans | 42 | 2020 | 48363 | 0.630 |
Why?
|
| Health Planning Guidelines | 2 | 2007 | 26 | 0.600 |
Why?
|
| Warfarin | 3 | 2020 | 102 | 0.590 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2008 | 506 | 0.580 |
Why?
|
| Ticlopidine | 2 | 2006 | 61 | 0.560 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 34 | 0.530 |
Why?
|
| Brain | 6 | 2007 | 1135 | 0.500 |
Why?
|
| Acute Disease | 8 | 2010 | 624 | 0.480 |
Why?
|
| Freezing | 1 | 2011 | 15 | 0.470 |
Why?
|
| Recovery of Function | 4 | 2019 | 193 | 0.460 |
Why?
|
| Embolism | 2 | 2008 | 31 | 0.440 |
Why?
|
| Thrombophilia | 1 | 2010 | 17 | 0.440 |
Why?
|
| Brain Injuries | 2 | 2013 | 121 | 0.420 |
Why?
|
| Aspirin | 2 | 2009 | 173 | 0.410 |
Why?
|
| Male | 22 | 2019 | 23420 | 0.400 |
Why?
|
| Cerebral Infarction | 2 | 2007 | 53 | 0.400 |
Why?
|
| Gadolinium | 1 | 2009 | 57 | 0.390 |
Why?
|
| Intracranial Embolism | 1 | 2009 | 25 | 0.390 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 309 | 0.390 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2008 | 4 | 0.390 |
Why?
|
| Behavior, Animal | 2 | 2007 | 175 | 0.380 |
Why?
|
| Brain Infarction | 1 | 2008 | 16 | 0.380 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 514 | 0.380 |
Why?
|
| Hyperoxia | 1 | 2008 | 11 | 0.380 |
Why?
|
| Research | 2 | 2009 | 187 | 0.380 |
Why?
|
| Contrast Media | 1 | 2009 | 282 | 0.350 |
Why?
|
| Biomedical Technology | 1 | 2007 | 5 | 0.340 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 21 | 0.340 |
Why?
|
| Rats, Wistar | 4 | 2013 | 172 | 0.330 |
Why?
|
| Telemedicine | 2 | 2009 | 207 | 0.320 |
Why?
|
| Middle Cerebral Artery | 1 | 2006 | 34 | 0.310 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2005 | 13 | 0.310 |
Why?
|
| Membrane Proteins | 1 | 2011 | 780 | 0.300 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 88 | 0.290 |
Why?
|
| Device Approval | 1 | 2005 | 10 | 0.290 |
Why?
|
| Diffusion | 5 | 2008 | 74 | 0.280 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 206 | 0.270 |
Why?
|
| Patient Selection | 3 | 2016 | 361 | 0.260 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 664 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 185 | 0.260 |
Why?
|
| Research Design | 2 | 2005 | 528 | 0.260 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 62 | 0.260 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2002 | 24 | 0.250 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 29 | 0.240 |
Why?
|
| Neuroimaging | 2 | 2013 | 71 | 0.240 |
Why?
|
| Heparin | 1 | 2002 | 107 | 0.230 |
Why?
|
| Disease Management | 1 | 2003 | 179 | 0.230 |
Why?
|
| Neurons | 2 | 2011 | 784 | 0.230 |
Why?
|
| Blood Pressure | 3 | 2010 | 479 | 0.230 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4230 | 0.230 |
Why?
|
| Astrocytes | 1 | 2002 | 106 | 0.220 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 375 | 0.220 |
Why?
|
| Risk Factors | 4 | 2019 | 4225 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 1055 | 0.200 |
Why?
|
| China | 1 | 2019 | 106 | 0.200 |
Why?
|
| Rivaroxaban | 1 | 2018 | 13 | 0.190 |
Why?
|
| Dabigatran | 1 | 2018 | 18 | 0.190 |
Why?
|
| Risk Assessment | 2 | 2019 | 1593 | 0.190 |
Why?
|
| Aged | 6 | 2020 | 10909 | 0.180 |
Why?
|
| Disability Evaluation | 1 | 2019 | 191 | 0.180 |
Why?
|
| Regional Blood Flow | 2 | 2008 | 93 | 0.170 |
Why?
|
| Hemorrhage | 3 | 2019 | 213 | 0.170 |
Why?
|
| Homes for the Aged | 1 | 2019 | 149 | 0.170 |
Why?
|
| Nursing Homes | 2 | 2020 | 531 | 0.170 |
Why?
|
| Neurology | 1 | 2016 | 22 | 0.170 |
Why?
|
| Protein C | 1 | 2016 | 28 | 0.170 |
Why?
|
| Secondary Prevention | 3 | 2018 | 128 | 0.170 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 855 | 0.170 |
Why?
|
| Registries | 1 | 2019 | 676 | 0.160 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 194 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2016 | 126 | 0.150 |
Why?
|
| Middle Aged | 4 | 2019 | 13617 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2020 | 4317 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1337 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 489 | 0.140 |
Why?
|
| Injections, Intravenous | 2 | 2005 | 147 | 0.140 |
Why?
|
| United States | 5 | 2020 | 6149 | 0.130 |
Why?
|
| Cerebral Hemorrhage | 2 | 2005 | 57 | 0.130 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 197 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 690 | 0.130 |
Why?
|
| Language | 1 | 2014 | 113 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 433 | 0.130 |
Why?
|
| Tetrazolium Salts | 2 | 2008 | 14 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2013 | 203 | 0.120 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2011 | 18 | 0.120 |
Why?
|
| Medicare | 3 | 2020 | 434 | 0.120 |
Why?
|
| Factor V Deficiency | 1 | 2010 | 1 | 0.110 |
Why?
|
| Antithrombin III Deficiency | 1 | 2010 | 2 | 0.110 |
Why?
|
| Protein S Deficiency | 1 | 2010 | 2 | 0.110 |
Why?
|
| Protein C Deficiency | 1 | 2010 | 3 | 0.110 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 217 | 0.110 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 11 | 0.110 |
Why?
|
| Female | 5 | 2019 | 26304 | 0.110 |
Why?
|
| Cell Death | 1 | 2011 | 248 | 0.100 |
Why?
|
| Cortical Spreading Depression | 1 | 2009 | 9 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 234 | 0.100 |
Why?
|
| Hospital Units | 1 | 2009 | 8 | 0.100 |
Why?
|
| Health Care Sector | 1 | 2009 | 20 | 0.100 |
Why?
|
| Magnetic Field Therapy | 1 | 2008 | 2 | 0.100 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 9 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2007 | 538 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2020 | 298 | 0.090 |
Why?
|
| Functional Laterality | 2 | 2006 | 122 | 0.090 |
Why?
|
| Species Specificity | 1 | 2009 | 322 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 165 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 246 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 147 | 0.090 |
Why?
|
| Radiography | 2 | 2006 | 337 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2010 | 884 | 0.090 |
Why?
|
| Peptides | 1 | 2011 | 501 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2010 | 454 | 0.090 |
Why?
|
| Injury Severity Score | 1 | 2007 | 71 | 0.090 |
Why?
|
| Equipment Design | 1 | 2008 | 274 | 0.090 |
Why?
|
| Virginia | 1 | 2007 | 13 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2009 | 364 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 606 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2042 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 15 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2007 | 189 | 0.080 |
Why?
|
| Rats, Inbred WKY | 1 | 2005 | 11 | 0.080 |
Why?
|
| Body Temperature | 1 | 2005 | 46 | 0.080 |
Why?
|
| Drug Industry | 1 | 2005 | 35 | 0.080 |
Why?
|
| Legislation, Drug | 1 | 2005 | 16 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2005 | 16 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 18 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 63 | 0.070 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 61 | 0.070 |
Why?
|
| Drug Approval | 1 | 2005 | 26 | 0.070 |
Why?
|
| Models, Animal | 1 | 2005 | 202 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 80 | 0.070 |
Why?
|
| Risk | 1 | 2005 | 388 | 0.070 |
Why?
|
| Software | 1 | 2007 | 325 | 0.070 |
Why?
|
| Aspirin, Dipyridamole Drug Combination | 1 | 2003 | 3 | 0.070 |
Why?
|
| Heart Rate | 1 | 2005 | 266 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2005 | 481 | 0.070 |
Why?
|
| Dipyridamole | 1 | 2003 | 46 | 0.070 |
Why?
|
| Oxygen | 1 | 2005 | 236 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 405 | 0.070 |
Why?
|
| Recurrence | 1 | 2005 | 510 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2003 | 120 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2020 | 2076 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2008 | 485 | 0.070 |
Why?
|
| Thrombosis | 1 | 2006 | 186 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2005 | 110 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2003 | 120 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2005 | 785 | 0.060 |
Why?
|
| Adult | 2 | 2009 | 13301 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 877 | 0.060 |
Why?
|
| Disease Progression | 1 | 2005 | 691 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2003 | 171 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 309 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 248 | 0.060 |
Why?
|
| Decision Making | 1 | 2004 | 322 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1186 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2007 | 2492 | 0.050 |
Why?
|
| Water | 1 | 2002 | 254 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 1962 | 0.050 |
Why?
|
| Drug Substitution | 1 | 2019 | 34 | 0.050 |
Why?
|
| Algorithms | 1 | 2004 | 886 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 38 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2018 | 57 | 0.050 |
Why?
|
| Mice | 1 | 2011 | 8986 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2019 | 272 | 0.050 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 76 | 0.040 |
Why?
|
| Urbanization | 1 | 2017 | 2 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 221 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 640 | 0.040 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 61 | 0.040 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 29 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2016 | 561 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2013 | 105 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2046 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 290 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 864 | 0.030 |
Why?
|
| Silicon | 1 | 2006 | 18 | 0.020 |
Why?
|
| Sutures | 1 | 2006 | 35 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 107 | 0.020 |
Why?
|
| Surface Properties | 1 | 2006 | 247 | 0.020 |
Why?
|